Differences

This shows you the differences between two versions of the page.

--- pharmaceutical_companies:biontech [2022/12/28 22:04]
liam
+++ pharmaceutical_companies:biontech [2023/04/08 21:42] (current)
liam old revision restored (2022/12/29 04:21)
@@ Line 3: / Line 3: @@
 {{ :pharmaceutical_companies:biontech_logo.svg.png?200|}}
-**BioNTech** is a German biotechnology company based in [[Germany:Mainz]], [[Germany]].
+**BioNTech** is a German biotechnology company based in [[Germany:Mainz]], [[:Germany]].
 ===== History =====
-BioNTech was founded in 2008 by [[Ugur Sahin]], [[Christoph Huber]] and [[Özlem Türeci]] with a seed investment of €150 million from the Strüngmann family, through its investment vehicle [[AT Impf]], and [[MIG Capital]].((//Amendment No. 3 to Form F-1 Registration Statement.// (2019, October 9). BioNTech; Securities and Exchange Commission. https://web.archive.org/web/20221228202950/https://investors.biontech.de/node/6751/html#toc))
+==== Founding ====
-==== Research and development ====
+BioNTech was founded in 2008 by [[:Ugur Sahin]], [[:Christoph Huber]] and [[:Özlem Türeci]] with a seed investment of €150 million from the Strüngmann family, through its investment vehicle [[:AT Impf]], and [[:MIG Capital]].((//Amendment No. 3 to Form F-1 Registration Statement.// (2019, October 9). BioNTech; Securities and Exchange Commission. https://web.archive.org/web/20221228202950/https://investors.biontech.de/node/6751/html#toc))
+==== mRNA research and development ====
+In August 2018, BioNTech announced that it had entered a "multi-year research and development (R&D) collaboration with [[pharmaceutical_companies:Pfizer]]" to "develop [[:mRNA]]-based vaccines for prevention of [[:influenza]] (flu)."((Maas, S., Woolford, J., & Alatovic, J. (2018, August 16). //BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza.// BioNTech. https://archive.vn/L9LUP)) Under the terms of the agreement, following BioNTech's completion of a first-in-human clinical study, Pfizer would assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines. BioNTech received $120 million upfront.
+In September 2019, BioNTech received a capital contribution of $55 million from the [[:Bill & Melinda Gates Foundation]], with the option of doubling that investment amount at a later date.((Boehler, M., Schweitzer, G., & May, S. (2019, September 4). //BioNTech Announces New Collaboration to Develop HIV and Tuberculosis Programs.// BioNTech. https://archive.vn/npENU))
 On October 16, 2019, [[:Nature]] published an article describing BioNTech's successes in testing experimental [[:immunotherapy|immunotherapy]] [[:vaccines|vaccines]] for [[:cancer]], and suggested the progress could be applied to solve problems like [[:rabies]] and [[:pandemic influenza]].((Dolgin, E. (2019). //Unlocking the potential of vaccines built on messenger RNA.// Nature, 574(7778), S10–S12. https://doi.org/10.1038/d41586-019-03072-8))
@@ Line 15: / Line 21: @@
 ==== COVID-19 ====
-On March 16, 2020, BioNTech announced its receipt of a $135 million investment from [[pharmaceutical_companies:Fosun Pharmaceuticals]] in exchange for 1.58 million shares in BioNTech and the future development and marketing rights of the [[:mRNA vaccines|mRNA vaccine]] [[:BNT162b2]] in [[:China]].((Burger, L. (2020, March 16). //BioNTech in China alliance with Fosun over coronavirus vaccine candidate.// Reuters. https://web.archive.org/web/20220720182255/https://www.reuters.com/article/biontech-fosunpharma-vaccine-collaborati/biontech-in-china-alliance-with-fosun-over-coronavirus-vaccine-candidate-idUSL8N2B90UW)) Also, BioNTech announced a collaboration with [[Pfizer]] to scale-up manufacturing capacity to provide worldwide supply in response to the pandemic. BioNTech and Pfizer would commercialize the vaccine worldwide except in China, which was already covered by BioNTech's agreement with Fosun.((Rose, A., O’Neill, L., Crowe, R., Alatovic, J., & Maas, S. (2020, April 9). //Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development.// Business Wire. https://web.archive.org/web/20220720183348/https://www.businesswire.com/news/home/20200409005405/en/Pfizer-and-BioNTech-Announce-Further-Details-on-Collaboration-to-Accelerate-Global-COVID-19-Vaccine-Development))
+On March 16, 2020, BioNTech announced its receipt of a $135 million investment from [[pharmaceutical_companies:Fosun Pharma]] in exchange for 1.58 million shares in BioNTech and the future development and marketing rights of the [[:mRNA vaccines|mRNA vaccine]] [[:BNT162b2]] in [[:China]].((Burger, L. (2020, March 16). //BioNTech in China alliance with Fosun over coronavirus vaccine candidate.// Reuters. https://web.archive.org/web/20220720182255/https://www.reuters.com/article/biontech-fosunpharma-vaccine-collaborati/biontech-in-china-alliance-with-fosun-over-coronavirus-vaccine-candidate-idUSL8N2B90UW)) Also, BioNTech announced a collaboration with [[Pfizer]] to scale-up manufacturing capacity to provide worldwide supply in response to the pandemic. BioNTech and Pfizer would commercialize the vaccine worldwide except in China, which was already covered by BioNTech's agreement with Fosun.((Rose, A., O’Neill, L., Crowe, R., Alatovic, J., & Maas, S. (2020, April 9). //Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development.// Business Wire. https://web.archive.org/web/20220720183348/https://www.businesswire.com/news/home/20200409005405/en/Pfizer-and-BioNTech-Announce-Further-Details-on-Collaboration-to-Accelerate-Global-COVID-19-Vaccine-Development))
 ===== Organization =====
+==== Collaborators ====
+BioNTech has products in various stages of development in partnership with:((//Amendment No. 3 to Form F-1 Registration Statement.// (2019, October 9). BioNTech; Securities and Exchange Commission. https://web.archive.org/web/20221228202950/https://investors.biontech.de/node/6751/html#toc))
+  * [[pharmaceutical_companies:Bayer]]
+  * [[pharmaceutical_companies:Eli Lilly]]
+  * [[pharmaceutical_companies:Genentech]]
+  * [[pharmaceutical_companies:Genevant Sciences]]
+  * [[pharmaceutical_companies:Genmab]]
+  * [[pharmaceutical_companies:Pfizer]]
+  * [[pharmaceutical_companies:Sanofi]]
+  * [[:Translational Oncology at the University Medical Center of Johannes Gutenberg University]] (TRON)
+  * [[:University of Pennsylvania]]
 ==== Investors ====
@@ Line 29: / Line 49: @@
   * [[:European Investment Bank]]
   * [[:Fidelity]]
-  * [[pharmaceutical_companies:Fosun Pharmaceuticals]]
+  * [[pharmaceutical_companies:Fosun Pharma]]
   * [[:German Federal Ministry of Education and Research]] (BMBF)
   * [[:Invus]]